Cargando…

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

BACKGROUND: CPX-351 (United States: Vyxeos(®); Europe: Vyxeos(®) Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leuke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortes, Jorge E., Lin, Tara L., Uy, Geoffrey L., Ryan, Robert J., Faderl, Stefan, Lancet, Jeffrey E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276472/ https://www.ncbi.nlm.nih.gov/pubmed/34256819 http://dx.doi.org/10.1186/s13045-021-01119-w

Ejemplares similares

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML
por: Uy, Geoffrey L., et al.
Publicado: (2022)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
por: Mitchell, Joshua D., et al.
Publicado: (2023)

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial
por: Cortes, Jorge E., et al.
Publicado: (2022)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML
por: Molica, Matteo, et al.
Publicado: (2022)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
por: Sherrill, B, et al.
Publicado: (2008)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
por: Matulonis, Ursula A., et al.
Publicado: (2019)

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
por: Bernhard, J, et al.
Publicado: (2008)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)
por: Shah, Ruchitbhai, et al.
Publicado: (2019)

Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo
por: Vincelette, Nicole D., et al.
Publicado: (2019)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
por: Wang, Qi, et al.
Publicado: (2018)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
por: Marcus, R, et al.
Publicado: (2010)

P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY
por: Ritchie, Ellen, et al.
Publicado: (2023)

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
por: Rautenberg, Christina, et al.
Publicado: (2021)

P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
por: Luca Morelli, Gian, et al.
Publicado: (2023)

Two repetition time saturation transfer (TwiST) with spill-over correction to measure creatine kinase reaction rates in human hearts
por: Schär, Michael, et al.
Publicado: (2015)

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
por: Lin, Tara L., et al.
Publicado: (2019)

CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
por: Urbantat, Ruth M., et al.
Publicado: (2021)

The TWI Workbook
por: Graupp, Patrick, et al.
Publicado: (2017)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer
por: Huang, Min, et al.
Publicado: (2018)

A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
por: Cocks, Kim, et al.
Publicado: (2019)

A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
por: Wang, J, et al.
Publicado: (2011)

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
por: Pelzer, Uwe, et al.
Publicado: (2017)

P530: CPX-351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION
por: Riva, Carola, et al.
Publicado: (2023)

TWI Case Studies
por: Dinero, Donald
Publicado: (2014)

Uy GL, Newell LF, Lin TL, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022;6(17):4989-4993.
Publicado: (2023)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
por: Vucinic, Vladan, et al.
Publicado: (2020)

Successful Treatment of Acute Myeloid Leukemia with CPX-351 in 2 Patients in the United Kingdom during the COVID-19 Pandemic
por: Munisamy, Sreetharan, et al.
Publicado: (2021)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
por: Fortin, Marie C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8ljet09j3hfn99d8pkr6ip7r5k